The annualESMO (European Society for Medical Oncology) congress, Europe's leading oncology event, was held this year in Berlin from October 17 to 21, 2025. Researchers, clinicians and experts from all over the world gathered to share the latest advances in oncology. The Centre Baclesse was particularly well represented, with several oral communications, posters and participation in scientific sessions, testifying to the dynamism and excellence of its teams in cancer research and management.
More than 30,000 participants from 150 countries on five continents share and discover the latest advances in cancer treatment.
Here are the various contributions from professionals at the Centre Baclesse:
1 Proffered Paper session: Supportive and palliative care
- 2802O - Home-based supervised physical activity (SPA) for metastatic cancer patients receiving oral targeted therapy: the AFSOS-Unicancer QUALIOR randomized phase 3 Study, by Pr Florence JOLY LOBBEDEZ.
1 Mini oral CNS Tumors session :
- Phase 1/2a study of concomitant radiotherapy with olaparib and temozolomide (TMZ) in unresectable high-grade gliomas patients (pts) - Results from the phase 2a (OLA-TMZ-RTE-01), by Dr Dinu STEFAN.
D. Stefan (MD, PhD student), J. Lequesne (PhD), P. Kubicek (MD), M.P. Sunyach (MD), Elisabeth Cohen-Jonathan Moyal (MD, PhD), J. Jacob (MD), M. Fontanilles (MD, PhD), J. Geffrelot (MD), M. Boone (MD), J. Riverain (MD), M. Ducloie (MD), G. Braux (MD), J. Lacroix (MD), F. Missohou (MD), M. Faisant (MD), E. Emery (MD, PhD), E. Girard (MD), J.M. Grellard (MSc), P. Lesueur (MD, PhD student), B. Clarisse (PharmD, PhD).
4 Posters :
- Poster FPN#2911TiP: Cog-Stim2: Remotely supervised computerized cognitive stimulation to reduce post-chemotherapy cognitive difficulties in patients treated for localized breast cancer, an ongoing phase 3 trial
Marie Bousquet, Marie Lange, Olivia Diaz, Justine Lequesne, Isabelle Durand-Zaleski , Estelle Guerdoux , Antonio Di Meglio, Olivier Rigal, Elise Deluche, Flora Courtault-Deslandes, Frédéric Fiteni, Kevin Bourcier, Cécile Agostini, Marine Cabourg, Lorene Seguin, Chankannira San, Adrien Estienne, Jean-Michel Grellard, Bénédicte Clarisse, Florence Joly.
- Poster FPN 467P: Pre-therapeutic neutrophil-to-lymphocyte ratio as prognostic factor in locally advanced or metastatic breast cancer treated with cyclin dependent kinase 4/6 inhibitors in first line: PEPSI study.
Louis BOISMOREAUPauline ROTTIER, Florian CLATOT, Justine LEQUESNE, Adeline MOREL, Christelle LEVY, Marianne LEHEURTEUR, Djelila ALLOUACHE, Alison JOHNSON, Ioana HRAB, Coraline DUBOT-POITELON, Carine SEGURA DJEZZAR, Clémence BOSCHER, Pauline DESBOIS, Chankannira SAN, Delphine BRIDELANCE, Amélie POULLAIN, Bénédicte CLARISSE, Alexandra LECONTE, François CHERIFI, George EMILE, François CHRISTY, Angelique DA SILVA
Dr Louis BOISMOIREAU was interviewed by cancero.net:
- Poster 2415: Access to 177LuPSMA-617 in metastatic castration-resistant prostate cancer (mCRPC) in France: comparative analysis with cabazitaxel using national hospital data
Denis Maillet, Barbara Roux, Jade Vadel, Aurore Tricotel, Donatien Collet, Camille Wiart, Quentin Dardonville, Elske Quak.
- Poster: Parcours-Tox, impact of monitoring by a nurse navigator on the management of gynecological cancer patients treated with intravenous systemic treatment.
Co-authors: Minoc Flavien, Justine Lequesne, Magalie Legablier, Anthony Moreau, Florian Quilan, Emeline Meriaux, Coraline Dubot-Poitelon, Gwenn Le Gall, François Cherifi, Pr Florence Joly.
Congratulations to all!
